Evidence map›Paper›PMID 30258943›Full record

ArticleGenes & diseases2018

Establishment and functional characterization of the reversibly immortalized mouse glomerular podocytes (imPODs).

Xinyi Yu, Liqun Chen, Ke Wu, Shujuan Yan, Ruyi Zhang, Chen Zhao, Zongyue Zeng, Yi Shu, Shifeng Huang, Jiayan Lei and 14 more

Erratum issuedOpen access · diamondAbstract read
In one paragraph

Article in Genes & diseases, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 27 papers.

0numbers the graph read from it
0cells of the map it votes in
27citing papers in PubMed
3.2field-weighted citation impact, top 8% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

27 citing papers in PubMed, 32 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Immortalization Reversibility in the Context of Cell Therapy Biosafety.International journal of molecular sciences · 2023
    Review
  5. Differentiated mouse kidney tubuloids as a novelFrontiers in cell and developmental biology · 2023
    Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Establishment and characterization of an immortalized epicardial cell line.Journal of cellular and molecular medicine · 2021
    Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

24 authors at 5 institutions in 2 countries.

Xinyi YuDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Liqun ChenDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Ke WuMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Shujuan YanMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Ruyi ZhangMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Chen ZhaoDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Zongyue ZengMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Yi ShuMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Shifeng HuangDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Jiayan LeiDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Xiaojuan JiDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Chengfu YuanMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Linghuan ZhangMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Yixiao FengDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Wei LiuDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Bo HuangMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Bo ZhangMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Wenping LuoMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Xi WangMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Bo LiuDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Rex C HaydonMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Hue H LuuMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Tong-Chuan HeMolecular Oncology Laboratory, Department of Orthopaedic Surgery and Rehabilitation Medicine, The University of Chicago Medical Center, Chicago, IL, 60637, USA.
Hua GanDepartments of Nephrology, Orthopaedic Surgery, Cardiology, General Surgery, Plastic Surgery, and Clinical Laboratory Medicine, The First Affiliated Hospital of Chongqing Medical University, Chongqing, 400016, China.
Molecular Oncology (United States) · USChongqing Medical University · CNUniversity of Chicago Medical Center · USFirst Affiliated Hospital of Chongqing Medical University · CNLanzhou University Second Hospital · CN

Funding

VIRAL ONCOLOGY CORE FACILITYP30CA014599 · NCI · UNIVERSITY OF CHICAGO · PI CHIEN-MIN KAO · 1985 to 2026
$122.1M
Re-Engineering Translational Research at the University of ChicagoUL1TR000430 · NCATS · UNIVERSITY OF CHICAGO · PI SOLWAY, JULIAN · 2012 to 2016
$20.2M
Regulation of beta-Catenin Signaling by Tyrosine PhosphorylationR01CA106569 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2006 to 2010
$1.3M
A genomewide discovery of chemoresistance-associated noncoding RNAs in human cancersR21CA226303 · NCI · UNIVERSITY OF CHICAGO · PI HE, TONG-CHUAN · 2018 to 2019
$381k
NCATS NIH HHS UL1 TR000430NCI NIH HHS P30 CA014599NCI NIH HHS R01 CA106569NCI NIH HHS R21 CA226303
6 · The paper itself

Abstract

Glomerular podocytes are highly specialized epithelial cells and play an essential role in establishing the selective permeability of the glomerular filtration barrier of kidney. Maintaining the viability and structural integrity of podocytes is critical to the clinical management of glomerular diseases, which requires a thorough understanding of podocyte cell biology. As mature podocytes lose proliferative capacity, a conditionally SV40 mutant tsA58-immortalized mouse podocyte line (designated as tsPC) was established from the Immortomouse over 20 years ago. However, the utility of the tsPC cells is hampered by the practical inconvenience of culturing these cells. In this study, we establish a user-friendly and reversibly-immortalized mouse podocyte line (designated as imPOD), on the basis of the tsPC cells by stably expressing the wildtype SV40 T-antigen, which is flanked with FRT sites. We show the imPOD cells exhibit long-term high proliferative activity, which can be effectively reversed by FLP recombinase. The imPOD cells express most podocyte-related markers, including WT-1, Nephrin, Tubulin and Vinculin, but not differentiation marker Synaptopodin. The imPOD cells do not form tumor-like masses

Indexed as

Chronic kidney diseaseFLP recombinaseGlomerular diseaseGlomerulusImmortalizationNephropathyPodocyteSV40 T antigen

Identifiers

PMID30258943
PMCPMC6147083
OpenAlexW2799659036

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.